Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 2/20 | 0.44 |
| ▸ | CDK8 | P49336 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31006330 | 0.96 | CCNC (0.43) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL9948762 | 0.92 | USP30 (0.46) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL17761437 | 0.92 | CCNC (0.47) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL2338577 | 0.92 | CCNC (0.49) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL31748166 | 0.90 | MAPT (0.42) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL29346991 | 0.88 | USP30 (0.45) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL1207913 | 0.86 | USP30 (0.41) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL769742 | 0.84 | USP2 (0.45) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL9948300 | 0.83 | USP30 (0.47) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL30690042 | 0.83 | USP30 (0.47) | CCNCCDK8USP2SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608839-A1 | SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS | Protego Biopharma, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-114369095-B | Aminopyrimidine compounds useful as SSAO inhibitors and methods for preparing the same | 伊莱利利公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-3746447-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2024-12-04 | — | — | EP | disclosed |
| US-20240174695-A1 | Spirocycle Containing Bicyclic Heteroaryl Compounds | PROTEGO BIOPHARMA, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-3630749-B9 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| CN-112204031-B | Spiro-lactam NMDA receptor modulators and uses thereof | 元羿生物科技(香港)有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4371562-A2 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024092040-A1 | SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS | PROTEGO BIOPHARMA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-3630749-B1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| CN-116023396-A | Nitrogen-containing spiro compound and medical application thereof | 中国医药研究开发中心有限公司 | 2023-04-28 | — | — | CN | disclosed |
| WO-2012055888-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012055888-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| WO-2011148962-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF | 大正製薬株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174695-A1 | Spirocycle Containing Bicyclic Heteroaryl Compounds | BCL6, BCL6B, BCL9 | CCNC 342/4885CDK8 2861/4885USP2 4207/4885 |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | REN, PKD1, NR3C2 | CCNC 1477/4885CDK8 2724/4885USP2 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.